Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans

Anti-Cancer Drugs

Volumn 7, Issue 8, 1996, Pages 893-896

  Lokiec, François ^a   Santoni, Joëlle ^a   Weill, Sophie ^a   Tubiana Hulin, Michèle ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

high dose; ifosfamide; pharmacokinetics; phenobarbital

Indexed keywords

IFOSFAMIDE; PHENOBARBITAL;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG INTERACTION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; OSTEOSARCOMA; PRIORITY JOURNAL; SOFT TISSUE SARCOMA;

EID: 0029774509     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199611000-00013     Document Type: Article

References (21)

1. Allen LM, Creaven PJ, Nelson P. Studies on the human PK of isophosphamide (NSC-109724). Cancer Treat Rep 1976; 60: 451-8.
2. Norpoth K, Müller G, Raidt H. Isolierung und Charakterisierung zweier haupt-metabolite von ifosfamid aus patienten-urin. Arzneim-Forscb (Drug Res) 1976; 25: 1376-7.
3. Bremmer DN, McCormick JS, Thompson JW. Clinical trial of isophosphamide (NSC-109724). Results and side effects. Cancer Treat Rep 1974; 58: 889-93.
4. Nelson RL, Allen LM, Creaven PJ. Pharmacokinetics of divided dose ifosfamide. Clin Pharmacol Ther 1976; 19: 365-70.
5. Fossa S, Talle K. Treatment of metastatic renal cancer with ifosfamide and mesna with and without irradiation. Cancer Treat Rep 1980; 64: 1103-8.
6. Lewis LD, Meanwell CA. Ifosfamide pharmacokinetics and neurotoxicity. Lancet 1990; 335: 175-6.
7. Pearcy R, Calvert R, Metha A. Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma. Cancer Chemother Pharmacol 1988; 22: 353-5.
8. Cohen MH, Creaven PJ, Tejada F. Phase I clinical trial of isophosphamide (NSC-109724). Cancer Chemother Rep 1975; 59: 751-5.
9. Gieron MA, Barak L, Estrada J. Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. J Neuro-oncol 1988; 6: 29-30.
10. Burton LC, James CA. Rapid method for the determination of ifosfamide and cyclophosphamide in plasma high-performance liquid Chromatography with solidphase extraction. J Chromatogr 1988; 431: 450-4.
11. Urien S. MicroPham-K, a microcomputer interactive program for the analysis and simulation of PK processes. Pharm Res 1995; 12: 1225-30.
12. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989; 49: 753-7.
13. Graham MI, Shaw IC, Souhami RL, Sidau B, Harper PG, Maclean AE. Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother Pharmacol 1983; 10: 192-3.
14. Watkin SW, Husband DJ, Green JA, Warenius HM. Ifosfamide encephalopathy: a reappraisal. Eur J Cancer Clin Oncol 1989; 25: 1303-10.
15. Wagner T, Heydrich D, Jork T, Voelcker G, Hohorst HJ. Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorimetric test. J Cancer Res Clin Oncol 1981; 100: 95-104.
16. Colvin M. The comparative pharmacology of cyclophosphamide and ifosfamide. Semin Oncol 1982; 9 (Suppl 1): 2-7.
17. Norpoth K. Studies on the metabolism of isophosphamide (NSC-109724) in man. Cancer Treat Rep 1976; 60: 437-43.
18. Jao JY, Jusko WJ, Cohen JL. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res 1972; 32: 2761-4.
19. Boddy AV, Cole M, Pearson ADJ, Idle JR. The kinetics of the autoinduction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995; 36: 53-60.
20. Chang TKH, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosfamide by cytochrome P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629-37.
21. Beaune P. Les cytochromes P-450 humains. Applications en pharmacologie. Therapie 1993; 48: 521-6.